Proactive Investors - Run By Investors For Investors

ReNeuron's Michael Hunt updates on product development

Michael Hunt, CFO at ReNeuron Group Plc (LON:RENE) chats to Proactive to update on the cell-based therapeutics specialist's research and development programmes.

Hunt says they're to increase the number of clinical sites in their PISCES III study from 25 to 40.

PISCES III is a phase IIb clinical study in the US of ReNeuron’s CTX cell therapy candidate for stroke disability.

First patient dosing in the study is expected in mid-2018 and top-line data from the study, as previously indicated, is expected in late 2019.

Meet Location Sciences Group PLC, Itaconix Plc, Shield Therapeutics PLC and WideCells Group at our event, London , 21 March 2019. Register here »
View full RENE profile View Profile

ReNeuron Group PLC Timeline

December 19 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use